Document:

Pursuant to 17 CFR 229.601(b)(10)(iv), confidential information (indicated by
    [***]) has been omitted from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. 

  Exhibit 10.11.7

   

  6th Amendment 

  to the Manufacturing Agreement

  entered into as of September 30th , 2010

   

  This Amendment 6 (“Amendment 6”) is made effective as of June 1st, 2017 (“Amendment 6 Effective Date”) by and between SANDOZ and Aegerion Pharmaceuticals, Inc., located at One Main Street,
    Cambridge, MA 02142, USA (“Aegerion”), and Sandoz GmbH, a company incorporated in Austria, with its office at Biochemiestrasse 10, A-6250 Kundl, Austria (“Sandoz”).

   

  WITNESSETH:

   

  WHEREAS, Aegerion and Sandoz are parties to a certain

    Contract Manufacturing Agreement in relation to Metreleptin SLD, dated as of September 30th 2010, as amended (the “Agreement”);

   

  WHEREAS, due to Aegerion’s increased demand and Sandoz’ limited storage capacity for Metreleptin,

    the parties wish to define the conditions upon which Sandoz may ship Metreleptin batches prior to Sandoz Batch Release for Aegerion to Fischer Bioservices, 1001 Aldridge Rd, Vacaville 98688 (USA) (“Aegerion’s Facilities”) or to other
    facilities designated by Aegerion;

   

  WHEREAS, the number of Metreleptin Batches to be shipped prior to Batch Release will
    depend upon the number of Metreleptin batches Manufactured and the available storage capacity at Sandoz and will depend on authorization by Aegerion Quality Assurance;

   

  WHEREAS, Aegerion and Sandoz desire to amend the Agreement to reflect mutually agreed upon revised
    terms in accordance with the provisions of this Amendment 6.

   

  NOW, THEREFORE, in consideration of premises the mutual covenants and agreements set forth herein
    and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Aegerion and Sandoz agree as follows:

   

  	1.	Definitions.

   

  Capitalized terms used herein, but not otherwise defined, shall have the meanings ascribed to them in the Agreement.

   

  	2.	Amendments.

   

  		2.1.	The parties hereby agree that Metreleptin batches may be shipped prior to Batch Release when authorized by Aegerion Quality Assurance;

   

  		2.2.	The parties hereby agree that it may be necessary to ship Metreleptin Batches which have finished manufacturing prior to Batch Release, if it has been agreed mutually
          between both parties.

   

  		2.3.	Shipments prior to Batch Release of Metreleptin Batches by Sandoz are subject to conditions defined in the Quality Agreement, as amended.

   

  
    1

    
      
 

  

  		2.4.	Sandoz is and shall be entitled to issue the relevant commercial invoice(s) upon any Metreleptin shipment. The payment for each of the Metreleptin Batches
          delivered prior to Batch Release is due in accordance with the current payment terms of [***] after the relevant Sandoz Release has occurred.

   

  		2.5.	Any delivery of a Metreleptin Batch prior to Batch Release shall be subject to the provisions of Section 12 (1) phrase 3 of the Agreement.

   

  		2.6.	Each shipment prior to Batch Release shall meet the preconditions per the Quality Agreement, it shall be labeled, transported and stored clearly labeled and designated as
          “Quarantine” on relevant transport documentation, and where applicable, storage documentation, and be accompanied by the following documents: (i) commercial invoice, (ii) Aegerion’s request for transfer prior to release, and (iii) memorandum on
          deviations and at this time available release results (v) Packing List (vi) USDA statement (vii) End Use Letter (viii) Material Safety Data Sheet. Aegerion may request a copy of the shipping announcement for information by Aegerion QA, Supply
          Chain, Customs, and B80 at the time the shipment is sent.

   

  		2.7.	Any Metreleptin quality disputes and/or non-conformance to the Specifications shall be subject to the provisions of Section 27 of the
          Agreement. For the avoidance of doubt, if the Metreleptin Batch(s) (delivered prior to Batch Release) do not pass the Release by Sandoz (after the material has arrived at Aegerion) due to reasons attributable to Sandoz in accordance with
          the Agreement, then Sandoz will be responsible for reimbursing Aegerion with the shipping, customs, other transportation and destruction charges; in addition, Sandoz shall cancel the invoice (or portion thereof), or issue credit if Aegerion has
          already paid the invoice, applicable to the nonconforming Batch(s). For the sake of clarity only, and consistent with the terms of delivery established in Section 12.1 of the Agreement, any risk of loss and other damage to any Metreleptin Batches

          shipped prior to Batch Release will pass to Aegerion once Sandoz has loaded said Batches onto Aegerion’s designated carrier.

   

  		2.8.	The recitals constitute an integral and substantial part of this Amendment.

   

  	3.	Reference to and Effect on the Agreement.

   

  3.1          On and after the Amendment 6 Effective Date, each reference to “this Agreement,” “hereunder,”
    “hereof,” “herein,” or words of like import shall mean and be a reference to the Agreement as amended hereby. No reference to this Amendment need be made in any instrument or document at any time referring to the Agreement, a reference to the Agreement
    in any of such instrument or document to be deemed to be a reference to the Agreement as amended hereby.

   

  3.2          Except as expressly amended by this Amendment 6, the provisions of the Agreement shall remain
    in full force and effect.

  
    2

    
      
 

  

  
    	4.	Counterparts.

  

   

  

  This Amendment 6 may be executed in any number of counterparts, each such counterpart shall be deemed to
    be an original instrument, and all such counterparts together shall constitute but one agreement. Any such counterpart may contain one or more signature pages. This Amendment 6 may be executed by facsimile signature pages.

   

  [The remainder of this page has been intentionally left blank, signature page follows]

  
    3

    
      
 

  

  IN WITNESS WHEREOF, the undersigned have caused this Amendment 6 to be executed and delivered on the date first written
    above.

    

  	Sandoz GmbH	 	Sandoz GmbH
	 	 	 	 	 
	Date:	01 Mar 2018	 	Date:	27 July 2017
	 	 	 	 	 
	By:	/s/ Johannes Reiter	 	By:	/s/ K. Brandenburg
	Name:	Mag. Johannes Reiter	 	Name:	Dr. K. Brandenburg
	Title:	Head Biotech Cooperations	 	Title:	Head Legal

   

  

  	Aegerion Pharmaceuticals, Inc.	 
	 	 	 
	Date:	24 July2017	 
	 	 	 
	By:	/s/ Joe Shulman	 
	Name:	Joe Shulman	 
	Title:	SVP, Global Technical Operations	 

   

  4Pursuant to 17 CFR 229.601(b)(10)(iv), confidential information (indicated by
    [***]) has been omitted from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. 

  Exhibit 10.11.8

  

   

  7th Amendment

    to the Manufacturing Agreement 

    entered into as of September 30th , 2010

  This Amendment 7 (“Amendment 7”) is made effective as of August 1, 2017 (“Amendment 7 Effective Date”) by and
    between Aegerion Pharmaceuticals, Inc., located at One Main Street, Cambridge, MA 02142, USA (“Aegerion”), and Sandoz GmbH, a company incorporated in Austria, with its office at Biochemiestrasse 10, A-6250 Kundl, Austria (“Sandoz”).

  WITNESSETH:

   

  WHEREAS, Aegerion and Sandoz are parties to a certain Contract Manufacturing Agreement in relation to Metreleptin

      SLD, dated as of September 30th 2010, as amended (the “Agreement”);

   

  WHEREAS, due to increased demand of Product needed by Aegerion for clinical trials and later commercialization
    Aegerion wish Sandoz to scale up the Process in Sandoz’ RPP4 Facility and Sandoz is willing to perform such activities and Manufacture certain Batches as described herein;

   

  NOW, THEREFORE, in consideration of premises, the mutual covenants and agreements set forth herein and for other
    good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Aegerion and Sandoz agree as follows:

   

  	1.	Definitions.

   

  Capitalized terms used herein, but not otherwise defined, shall have the meanings ascribed to them in the Agreement.

   

  	2.	Amendments.

   

  	

        	2.1.	A new DEFINITION is added to Sec. 1(1) of the Agreement:

   

  “RPP4+ Process” means the Process (as defined in Sec. 1 (1) of the Agreement) as adapted for the purpose of increasing the throughput in the RPP4
    Facility.

   

  	

        	2.2.	Sandoz shall Manufacture Product based on the RPP4+ Process in RPP4 in quantities as defined in Schedule 1.

   

  	

        	2.3.	Sandoz shall use commercially reasonable efforts to implement in a timely manner the modifications to the RPP4 Facility as set forth in
          Schedule 2 required for the scale-up of the Process to become the RPP4+ Process (collectively the “4+ Facility Modifications”), including procuring, engineering, installing, testing and validating the applicable equipment and systems, in
          accordance with the budget set forth in Schedule 1. If the implementation and validation of the RPP4+ Process fails for reasons not attributable to Sandoz, remaining capacity, if any, shall be used for Manufacture of commercial quantities
          according to the currently established Process. Events of single out-of-specification results during the RPP4+ Process shall be

   

  	Confidential	1	 

   

  
    
      
 

  

  handled according to the current CMA and QAA, as amended. Costs payable to Sandoz under this amendment 7 shall not be reimbursed
    to Aegerion.

   

  All assets for the 4+ Facility Modifications will be purchased by Sandoz on its own behalf. Sandoz shall become the sole owner of
    all assets. Sandoz shall be responsible for maintaining such assets and for all of the costs and expenses related thereto in order to keep them in acceptable working condition.

   

  Aegerion shall reimburse Sandoz for all reasonable costs and expenses, including without limitation capital expenditures, incurred
    by Sandoz for obtaining and installing the assets, the Facility idle time required for installation and for the 4+ Facility Modifications (all of the foregoing, collectively, the “4+ Facility Modification Costs”) as follows: Sandoz shall be entitled to
    invoice, and Aegerion shall pay to Sandoz, such 4+ Facility Modification Costs estimated as set forth in Schedule 1, up to a maximum aggregate amount of [***].

   

  	

        	2.4.	Aegerion has paid [***] in [***] and [***] in [***] as a pre-payment for the campaign [***] and the 4+ Facility Modification Costs
          (purchase order [***] dated [***]). The remaining amount of the 4+ Facility Modification Costs shall be invoiced upon the start of the [***] campaign. For all future orders above [***], Aegerion shall pay in advance [***] of the difference
          between [***] and the actual value of the sum of all purchase order(s) of the same year. Sandoz shall issue an invoice for the Prepayment upon confirmation of the order by Sandoz and Aegerion shall pay not later than [***] after receipt of the
          invoice.

   

  	

        	2.5.	Upon delivery of the relevant Batch and the related certificates for the Batch to Aegerion, Sandoz shall invoice the full costs for
          each such Batch crediting [***] of the Prepayment (corresponding to the nine Batches to be Manufactured) to each such invoice or, for future campaigns, the pro rata amount of the prepayment based on the number of batches produced. The amounts to
          be prepaid, as described in the paragraph, is referred to individually and collectively as “Prepayment”.

   

  	

        	2.6.	The parties hereby agree that Metreleptin Batches may be shipped prior to Batch Release when authorized by Aegerion and Sandoz Quality
          Assurance according to Amendment 6.

   

  	

        	2.7.	If the campaign [***] (refer to purchase order [***], dated [***]) needs to be split into [***] due to production commitments for an
          alternate product, which cannot be rescheduled, cost for an additional change-over will be applicable for campaign [***] as outlined in Schedule 3.

   

  	

        	2.8.	The recitals constitute an integral and substantial part of this Amendment

   

  	

        	3.	Reference to and Effect on the Agreement.

   

  3.1           On and after the Amendment 7 Effective Date, each reference to “this Agreement,” “hereunder,” “hereof,” “herein,” or
    words of like import shall mean and be a reference to the Agreement as amended hereby. No reference to this Amendment need be made in any instrument or document at any time referring to

   

  	Confidential	2	 

   

  
    
      
 

  

  the Agreement, a reference to the Agreement in any of such instrument or document to be deemed to be a reference to the Agreement as amended hereby.

   

  3.2           Except as expressly amended by this Amendment 7, the provisions of the Agreement shall remain in full force and effect.

   

  	4.	Counterparts.

   

  This Amendment 7 may be executed in any number of counterparts, each such counterpart shall be deemed to be an original
    instrument, and all such counterparts together shall constitute but one agreement. Any such counterpart may contain one or more signature pages. This Amendment 7 may be executed by facsimile signature pages.

   

  	Confidential	3	 

   

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned have caused this Amendment 7 to be executed and delivered on the date first written above.

   

  	Sandoz GmbH	

        	Sandoz GmbH	 
	 	 	 	 	 
	Date:	19/02/2018	Date:	Feb 07, 2018	 
	 	 	 	 	 
	By:	/s/ Klaus Brandenburg	By:	/s/ Johannes Reiter 	 
	Name:	Dr. Klaus Brandenburg	
          Name:

        	Mag. Johannes Reiter	 
	Title:	Head Legal	Title:	Head Biotech Cooperations	 

   

  	Aegerion Pharmaceuticals, Inc.	 
	 	 
	Date: 	28 Feb 2018	 
	 	 	 
	By:	/s/ Joseph Shulman 	 
	Name: 	Joseph Shulman	 
	Title: 	Senior Vice President, Global Technical Operations  

   

  	Confidential	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]